Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis

Documenti analoghi

• Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy
  di: Robbin Itzler, et al.
  Pubblicazione: (2024)
• Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
  di: Robert Klamroth, et al.
  Pubblicazione: (2024)
• Expert United Kingdom consensus on the preservation of joint health in people with moderate and severe haemophilia A: A modified Delphi panel
  di: Mike Laffan, et al.
  Pubblicazione: (2024)
• Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease
  di: Pongpak Pongphitcha, et al.
  Pubblicazione: (2024)
• EAHAD haemophilia gene therapy clinical outcome database (EAHAD‐GTD)
  di: Wolfgang Miesbach, et al.
  Pubblicazione: (2024)